fashion -WSS

fashion

author：hotspot 2025-09-03 03:21:39 - browse：6

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： HHS's proposed rule does nothing to address the climate crisis

WSS

AI for drug discovery: Experts on separating hype from reality

As billionaires fund anti

As health system earnings go up, health insurance stocks go down

Pharma’s losing bet in New Jersey

Warren pushes Witty on UnitedHealth's control over physicians

The world needs the new pandemic treaty

hotspot

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

Stroke rates rising, especially in working

Alkermes shareholders re

AI for drug discovery: Experts on separating hype from reality

Hepatitis C has a cure — but many Americans still lack access to it

AltruBio raises $225 million to develop ulcerative colitis drug

Anesthesiologist group: stop taking Ozempic before surgery

As billionaires fund anti

Novavax promises a turnaround & Lilly roils the obesity market

AI for drug discovery: Experts on separating hype from reality

leisure time

The effects of a landmark ruling on DNA ownership are becoming clearer

Congress: Prevent baby formula shortages by passing a new bill

Clinicians often fail to acknowledge the pain caused by long Covid

AltruBio raises $225 million to develop ulcerative colitis drug

Protect nursing home residents from future pandemics

As health system earnings go up, health insurance stocks go down

focus

leisure time

focus

Wikipedia